<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03695107</url>
  </required_header>
  <id_info>
    <org_study_id>XY3-PTH1708A01</org_study_id>
    <nct_id>NCT03695107</nct_id>
  </id_info>
  <brief_title>Clinical Study on the Effect of PTH on CYP3A4 Activity</brief_title>
  <official_title>Clinical Study on the Effect of PTH on CYP3A4 Activity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Third Xiangya Hospital of Central South University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The Third Xiangya Hospital of Central South University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Parathyroid hormone (PTH) may play an important role in the down-regulation of CYP3A4
      expression induced by Chronic kidney diseases (CKD). In the study of molecular mechanism, the
      research group found that the expression of CYP3A2 metabolic enzyme in rat liver decreased in
      the state of CKD.And PTH may down-regulate the expression of CYP3A4 metabolic enzyme by
      inhibiting the expression of Nuclear factor- Kilobuse (NF-kB) p65 subunit
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 2, 2019</start_date>
  <completion_date type="Anticipated">September 10, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 10, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>the concentration of nifedipine</measure>
    <time_frame>at 5-7days</time_frame>
    <description>the concentration of nifedipine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>24-hour ambulatory blood pressure</measure>
    <time_frame>at 1 day and 7day</time_frame>
    <description>mean blood pressure</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Chronic Kidney Diseases</condition>
  <arm_group>
    <arm_group_label>XBDP1-</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>XBDP2-</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nifedipine controlled released tablets</intervention_name>
    <description>lower blood pressure</description>
    <arm_group_label>XBDP1-</arm_group_label>
    <arm_group_label>XBDP2-</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Chronic renal function associated with hypertension
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Chinese male or female subjects with an age of 18 or older were included;

          -  The clinical physician diagnosed CKD with hypertension;

          -  The physician decided that nifedipine controlled release tablets should be given.

          -  Subjects agree to the study protocol, clinical and follow-up time, and sign the
             informed consent after the approval of the ethics committee;

          -  Subjects will be able to communicate well with the investigator and will be able to
             complete the study as required.

        Exclusion Criteria:

          -  Patients with CKD requiring dialysis treatment;

          -  Other clinical reasons that may be considered inappropriate for inclusion by
             clinicians.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yang GuoPing, doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Third Xiangya Hospital of Central South University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yang Guoping, doctor</last_name>
    <phone>0086 0731 88618326</phone>
    <email>ygp9880@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Third Xiangya Hospital of Central South University , , China,</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yang Guoping, professor, doctor</last_name>
      <phone>0086 0731 88618326</phone>
      <email>ygp9880@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 17, 2018</study_first_submitted>
  <study_first_submitted_qc>October 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2018</study_first_posted>
  <last_update_submitted>September 17, 2019</last_update_submitted>
  <last_update_submitted_qc>September 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nifedipine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

